 RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021 Two new analyses of Movantik naloxegol data evaluated the safety and efficacy of Movantik in a subgroup of patients aged 65 years -- Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placebo were evaluated across high and low opioid dosages -- Movantik is the U.S. market-leading oral peripherally acting mu-opioid receptor antagonist PAMORA, approved to treat opioid-induced constipation in adults with chronic non-cancer pain TEL AVIV, ISRAEL and RALEIGH, NC ACCESSWIRE September 7, 2021 RedHill Biopharma Ltd. 